SOURCE: Equity Markets Inc.

September 16, 2011 09:05 ET

Global Situation & Resulting Influences - Research Report on Transcept Pharmaceuticals, Inc. and Somaxon Pharmaceuticals, Inc.

MACAU--(Marketwire - Sep 16, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) and Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX). Full content and research is available at www.EquityMarketsInc.com/research.php?id=TSPT+SOMX.

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed Transcept Pharmaceuticals, Inc. for its current position within the healthcare industry. Transcept Pharmaceuticals, Inc., formerly Novacea, Inc., is a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in neuroscience. The full research report on Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) is available here: www.EquityMarketsInc.com/research.php?id=TSPT.

World Street has featured Somaxon Pharmaceuticals, Inc. for its development within the healthcare industry. Somaxon Pharmaceuticals, Inc. (Somaxon) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The full research report on Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) is available here: www.EquityMarketsInc.com/research.php?id=SOMX.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information